Clinical trials: Neoplasm Circulating Cells
Glioblastoma, Molecular Disease
Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.
Glioblastomas (GBM) are rare tumors of poor prognosis and their treatment is based on surgery followed by radiochemotherapy. Clinical and imaging evaluation is not always straightforward: the more or less complete surgery, the…
- Trial name
- Bi-GLAM (NCT03115138)
- Testing
- Correlation between molecular anomalies of the primary tumor and circulating tumor DNA
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Melanoma
Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients
This trial is a translational proof-of-concept, open-label, prospective cohort study of 60 patients aiming to identify the clinical markers and/or biomarkers associated with therapeutic response to immune checkpoints inhibitors…
- Trial name
- IMMUSPHINX (NCT03627026)
- Testing
- Blood samples will be collected at different time points:
- Where
- 2 sites in France
- Volunteers
- 78 people
- Sponsor
- Institut Claudius Regaud
Metastatic Urothelial Carcinoma
A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)
Platinum-based chemotherapy remains the standard of care for advanced/metastatic unresectable bladder cancer. The JAVELIN Bladder 100 and HCRN GU14-182 trials showed that maintenance immune checkpoint inhibition(ICI) for those…
- Trial name
- CARMA (NCT06050954)
- Testing
- Pembrolizumab (200mg), Pembrolizumab (400mg), Monitoring
- Sponsor
- Fox Chase Cancer Center
Carcinoma, Non-Small-Cell Lung, Brain Metastases
Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain Metastasis
Collection of ctDNA and TCR data to predict the efficacy and prognosis of brain radiotherapy in patients with brain metastases from non-small cell lung cancer (NSCLC) in a comprehensive manner
- Trial name
- NCT05737589
- Testing
- Whole-brain radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xiaorong Dong
Small Cell Lung Cancer
Proteomics in Small Cell Lung Cancer
The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.
- Trial name
- SCLC-OMICS (NCT05623956)
- Where
- Denmark
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Aalborg University Hospital
HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
This research is being conducted to understand if treatment can be tailored for participants with HPV-related oropharynx cancers using both clinical features (stage of the tumor, smoking status) combined with an investigational…
- Conditions
- HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage, HPV-Related Squamous Cell Carcinoma
- Trial name
- NCT04900623
- Testing
- NavDx HPV ctDNA Testing, Radiotherapy, Chemotherapy drug
- Where
- 2 sites in United States
- Volunteers
- 145 people
- Sponsor
- Jonathan Schoenfeld, MD, MPH
Colorectal Cancer, Metastasis
PET-CT and Circulating Tumor Cells in Colorectal Cancer
The purpose of this study is to identify an early indicator of drug efficacy in patients with advanced colorectal cancer - a prospective evaluation of circulating tumor cells, positron-emission tomography scan and RECIST criteria.
- Trial name
- NCT01163305
- Testing
- Chemotherapy
- Where
- Hong Kong
- Volunteers
- 84 people
- Sponsor
- Chinese University of Hong Kong
Colon Cancer
Frequency of Circulating Tumour Cells in Stage II and Stage III Colon Cancer Patients
This study will determine whether a new diagnostic test called the Cell Search Assay can detect circulating colon cancer cells in patients who have had surgery for colon cancer and had visible cancer removed.
- Trial name
- NCT00351572
- Testing
- Cell Search Assay
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Alberta Health services
HER2-positive Metastatic Breast Cancer, Ovarian Cancer
Feasibility of a New Technology for Isolating Circulating Tumour Cells
This is a prospective interventional single-site research with a collection of biological samples. The primary objective of the trial is to assess the ability of the "new technology" to isolating circulating tumor cells (CTC) in…
- Conditions
- HER2-positive Metastatic Breast Cancer, Ovarian Cancer, Hormone-resistant Prostate Cancer, Circulating Tumor Cell
- Trial name
- CTC-SMMiL-E (NCT03979339)
- Testing
- Blood sample collection
- Where
- France
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Centre Oscar Lambret
Colorectal Neoplasms
Prognostic Value of Circulating Tumoral Free DNA Versus Circulating Tumoral Cells in Patients With Colorectal Cancer Stage II-III
After curative surgical resection, detection of metastatic lymph node remains the main prognostic validated criteria on which is based the decision of adjuvant therapy.
- Trial name
- CTC (NCT02556281)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 216 people
- Sponsor
- University Hospital, Rouen
Next-Generation-Sequencing
CIRculating Cell-free nUcLeic Acids in Cancer Therapy Monitoring -01
In cooperation with the molecular tumor board of the University Hospital Tübingen (UKT), a prospective collection of blood samples during the course of therapy is planned.
- Trial name
- CIRCULATING-01 (NCT05871593)
- Testing
- Molecular genetic diagnostic
- Volunteers
- 200 people
- Sponsor
- University Hospital Tuebingen
HPV, Oropharyngeal Squamous Cell Carcinoma
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
In this research study the investigators are examining a blood test to detect HPV DNA in the blood that can possibly detect cancer recurrence earlier than with standard surveillance measures.
- Trial name
- NCT04965792
- Testing
- Screening
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Dana-Farber Cancer Institute
Clear Cell Renal Cancer, Circulating Tumor Cells
Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer
Circulating tumor cells (CTCs) have prognostic value in several tumor types, and increasing evidence suggests that molecular characterization of CTCs can serve as a "liquid biopsy" to understand and address treatment resistance.
- Conditions
- Clear Cell Renal Cancer, Circulating Tumor Cells, Circulating Endothelial Cells, Prognostic Biomarkers
- Trial name
- NCT02499458
- Testing
- None- observational study
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Carcinoma, Hepatocellular, Neoplastic Cells, Circulating
Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
This study is designed to prospectively evaluate whether post-hepatectomy adjuvant transcatheter arterial chemoembolization (TACE) is effective in reducing early recurrence in HCC patients with preoperative CTC ≥2.
- Trial name
- NCT02631499
- Testing
- TACE, Epirubicin, lipiodol
- Where
- 6 sites in China
- Volunteers
- 256 people
- Sponsor
- Fudan University
Prostate Cancer
Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity
This clinical study is conducted to develop a new test to identify prostate cancer patients at highest risk of radiotherapy-related complications, especially related to gastrolintestinal (GI) toxicities.
- Trial name
- NCT04580667
- Testing
- Collection of plasma samples
- Where
- 5 sites in United States
- Sponsor
- DiaCarta, Inc.
Stomach Neoplasms, Metastasis
Detection of CTC and ctDNA in the Diagnosis of Metastasis in Gastric Cancer
To investigate the value of CTCs and ctDNA in the diagnosis of metastasis in ascites/peritoneal flushing fluid and blood; To investigate the influence of laparoscopic CO2 pneumoperitoneum establishment on peritoneal and…
- Trial name
- CTC_ctDNA (NCT05208372)
- Testing
- CTC test, ctDNA test
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- First Hospital of China Medical University
Merkel Cell Carcinoma
Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma
The goal of this prospective observational study is to evaluate the presence of circulating tumoral cells in patients over 18 with a stage I-III resectable Merkel cell carcinoma after the initial therapeutic sequence of surgery…
- Trial name
- MERCCALIBI (NCT06448611)
- Testing
- Blood Test
- Volunteers
- 25 people
- Sponsor
- University Hospital, Montpellier
Carcinoma, Non-small-cell Lung Cancer
Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA
Targeted next generation sequencing (NGS) provides a promising method for diagnostic purposes by enabling the simultaneous detection of multiple gene mutations.
- Conditions
- Carcinoma, Non-small-cell Lung Cancer, Thoracic Neoplasms
- Trial name
- NCT02833467
- Volunteers
- 45 people
- Sponsor
- Peking University People's Hospital
Esophageal Squamous Cell Carcinoma
Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
The goal of this observational study or is to explore the correlation between dynamic changes in postoperative circulating tumor DNA (ctDNA) and recurrence risk using a novel, tumor-informed ctDNA detection technique, thus laying…
- Trial name
- NCT06561178
- Testing
- molecular residual disease detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Lung Cancer, Pulmonary Neoplasm
Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management.
- Trial name
- BioMolCTC (NCT06546007)
- Testing
- CTC-DNA
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Rarecells Diagnostics SAS